

## Special Issue

# Hairy Cell Leukemia and Related Disorders—Current Progress in Biology and Treatment

### Message from the Guest Editors

Classic hairy cell leukemia (HCL) is a rare B-cell leukemia with an incidence of 0.3 per 100,000 yearly, characterized by pancytopenia, splenomegaly, and infection susceptibility. HCL-variant (HCLv) shares features with both classical HCL and B-cell prolymphocytic leukemia, and alongside other HCL-like diseases, is closely related to splenic lymphomas. The WHO's fifth edition classifies these as splenic B-cell lymphoma/leukemia with prominent nucleoli. Treatment for classic HCL primarily involves purine nucleoside analogs (cladribine, pentostatin), while BRAF inhibitors (vemurafenib, dabrafenib) are effective in relapsed cases. New therapies, including BTK inhibitors and venetoclax, are under investigation. HCLv treatment remains challenging, and despite advances, these diseases are incurable, highlighting the need for deeper biological understanding and novel therapies. For this Special Issue of *Cancers*, we welcome original research and review articles that provide an overview of the most recent advances and future challenges for the diagnosis and treatment of classic HCL and related disorders, including HCL-variant, SDRPL and other diseases.

### Guest Editors

Prof. Dr. Ewa Robak

Department of Dermatology, Medical University of Lodz, Lodz, Poland

Prof. Dr. Tadeusz Robak

Department of Hematology, Medical University of Lodz, Lodz, Poland

### Deadline for manuscript submissions

closed (30 November 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/199196](https://mdpi.com/si/199196)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)